Implications of targeting statin treatment at four CHD risk levels, showing cost per life year gained at 4.5% annual CHD risk, and marginal cost per life year gained by extending treatment to 3.0%, 2.0%, and 1.5% annual CHD risk levels
| CHD events per year | ||||
|---|---|---|---|---|
| 4.5% | 3.0% | 2.0% | 1.5% | |
| Main results | ||||
| Gross discounted, lifelong treatment with simvastatin | £5100 | £8200 | £10700 | £12500 |
| Sensitivity analyses | ||||
| Net discounted, lifelong treatment with simvastatin | £4300 | £7500 | £10100 | £11800 |
| Gross undiscounted, lifelong treatment with simvastatin | £3200 | £4500 | £5500 | £6100 |
| Gross discounted, 5 year treatment with simvastatin | £8200 | £15800 | £22100 | £26800 |
| Gross discounted, lifelong treatment with pravastatin | £7400 | £12000 | £15600 | £18200 |
| Gross discounted, lifelong treatment with simvastatin | ||||
| RRR 34% (4S) | – | £6600 | £7300 | – |
| RRR 22% (WOSCOPS) | – | £10700 | £11800 | – |
RRR, relative risk reduction for all cause mortality. These sensitivity analyses do not apply to 4.5% and 1.5% CHD risk levels because these estimates were based directly on trial results.